The CEO of Bank of America let it slip this week, almost casually, like it was pocket change: his company spends a quarter of a billion dollars a year on GLP-1 drugs for employees. A quarter. Billion. On Ozempic, Wegovy, and their skinny cousins. That's not a health benefit. That's a line item on the balance sheet that could fund a small war.
Let me put that in perspective. $250 million is more than the annual GDP of some Pacific island nations. It's enough to hire 5,000 nurses at $50,000 a crack. But no, we're injecting it into the abdomens of bankers who want to fit into their slim-fit suits. Is this progress, or are we just medicating our way out of a problem we refuse to confront?
The numbers behind this aren't pretty. GLP-1 drugs — the class that includes semaglutide, the active ingredient in Ozempic and Wegovy — cost companies roughly $1,000 to $1,500 per patient per month in 2026. That's $12,000 to $18,000 a year per employee. And demand isn't slowing. It's exploding. A recent Kaiser Family Foundation survey found that nearly one in eight employers now cover these drugs, up from just 4% in 2023. The pharmacy benefit managers are rubbing their hands with glee.
The Bottom Line Is Getting Fatter
Bank of America's CEO, Brian Moynihan, didn't frame this as a crisis. He framed it as a prudent investment. "We have 200,000 employees," he said at a conference this week, "and we're spending $250 million a year on these drugs. It's expensive, but we think it's worth it."
Worth it for whom? For the employee who loses 15% of their body weight and avoids diabetes? Sure. For the employer who sees lower absenteeism and higher productivity? Possibly. But let's not pretend this is charity. This is hard-nosed capitalism. An obese workforce costs a company money — in healthcare claims, in lost days, in presenteeism. If a pill costs less than the alternative, they'll buy the pill.
But here's the uncomfortable truth: these drugs are not a miracle. They're a maintenance drug. Stop taking them, and the weight comes back — 80% of it within a year, according to a 2024 study in JAMA. So BofA isn't paying a one-time cost. They're paying for a lifetime subscription to a drug that may or may not work long-term. And the clinical trials don't go beyond five years. We have no idea what 20 years of semaglutide does to a human body. The drug has only been on the market since 2017.
The Hidden Tax on Everyone Else
Here's the part that really grinds my gears. Bank of America isn't just spending its own money. It's spending your money. Every dollar spent on these drugs is a dollar not spent on raises, or bonuses, or keeping the branch open on Main Street. And when an employer like BofA covers these drugs, it drives up premiums for everyone — including those who don't work for a megabank. The insurance pool is shared. The costs are passed along.
But wait, it gets worse. The demand for GLP-1 drugs has strained supply chains, and that's causing shortages of these drugs for people who need them for diabetes, not just weight loss. Type 2 diabetics — who actually need semaglutide to control blood sugar — are getting rationed supply because healthy-but-chubby executives want to drop 20 pounds before vacation. That's not just unfair. It's evil.
I'm not saying obese people don't deserve treatment. I'm saying we've created a system where the rich get the drug, the poor get the diabetes, and the shareholders get the bill. Because let's be clear: these drugs aren't cheap. And the manufacturers — Novo Nordisk, Eli Lilly — are making record profits. Novo's market cap tripled in 2024. They're printing money faster than the Fed.
Is Anyone Asking the Obvious Question?
Maybe the real question isn't how to pay for these drugs, but why we need them in the first place. We've engineered an environment that makes us fat — ultra-processed food, desk jobs, screens that keep us glued to our butts — and then we turn around and pay billions to pharma to fix the symptom. It's like putting a band-aid on a gunshot wound.
And don't even get me started on the side effects. Gastroparesis, which is paralyzed stomachs. Pancreatitis. Gallbladder disease. These aren't rare. The FDA's adverse event database has thousands of reports. But hey, if you lose 15% of your body weight and can't keep a meal down, that's a price worth paying?
We're in a moment where the bluntest tool we have for obesity is a chemical that mimics a hormone. We're sticking ourselves with needles because we can't say no to a double cheeseburger. And the ultimate irony? The drug itself is expensive, but the infrastructure to prevent obesity — sidewalks, parks, healthy food access — is dirt cheap. We just don't want to build it.
The Verdict on BofA's Gamble
So what do we make of Bank of America's quarter-billion-dollar bet? It's a bet that our bodies are beyond repair, that we can't change our behavior, that a syringe is a better solution than a salad. It's a bet that treats big business's workforce as a capital expense, not as human beings.
But here's the thing: if you're a banker at BofA, you're probably thrilled. You get a $1,500-a-month drug for a $25 copay, and you can finally fit into your wedding tux again. If you're a shareholder, you might be worried. Those costs come out of earnings, and GLP-1s are just the beginning. If the trend continues, healthcare costs could eat 30% of corporate profits by 2030.
And if you're a taxpayer? You're subsidizing all of it, through tax deductions for employer-paid premiums and through Medicare and Medicaid, which cover these drugs too. So we all have skin in this game — whether we like it or not.
"We're paying to make our employees skinny because we can't make our society healthy."
At the end of the day, this isn't about Bank of America. It's about what we value as a culture. We value quick fixes over lasting change. We value productivity over well-being. We value a profit margin over a public park. And until we confront that, we'll keep spending billions on drugs that make us thinner but not healthier, richer for pharma but poorer for everyone else.
So go ahead, take your Ozempic. But know this: every shot is a mirror, and it's reflecting a society that would rather medicate itself than fix the root cause. That's a hard pill to swallow. And it's not covered by insurance.
